Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Luigi Nocera,Pierre I. Karakiewicz,Mike Wenzel,Zhe Tian,Shahrokh F. Shariat,Fred Saad,Felix K.-H. Chun,Alberto Briganti,Anil Kapoor,Aly-Khan A. Lalani

Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

2021

Luigi Nocera
Pierre I. Karakiewicz
Mike Wenzel
Zhe Tian
Shahrokh F. Shariat
Fred Saad
Felix K.-H. Chun
Alberto Briganti
Anil Kapoor
Aly-Khan A. Lalani

Background:Four recent first-line clinical trials leveraging immune-oncology agents demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide formal comparisons among...

Keywords:

Renal cell carcinoma
Clinical trial
Internal medicine
Adverse effect
Oncology
overall survival
Sunitinib
Medicine
first line treatment
Meta-analysis
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations